

AstraZeneca suffers diabetes drug setback for COVID

12 April 2021



clots, and by conflicting recommendations over its use.

© 2021 AFP

Credit: Unsplash/CC0 Public Domain

British pharmaceutical giant AstraZeneca on Monday said that following a trial, its diabetes drug Farxiga was not successful in treating COVID patients at risk of severe complications.

AstraZeneca, whose separate COVID vaccine rollout has been hampered by [health concerns](#), said its trial "assessing the potential of Farxiga to treat patients hospitalised with COVID-19 who are at risk of developing serious complications... did not achieve statistical significance".

The trial was carried out alongside Saint Luke's Mid America Heart Institute and looked at potential complications including diabetes and heart failure.

"While the trial did not achieve [statistical significance](#), the findings are very interesting and valuable, and will inform future clinical science," Saint Luke's cardiologist Mikhail Kosiborod said in a joint statement.

Public confidence in AstraZeneca's COVID-19 vaccine has meanwhile been badly shaken by reports linking it to rare, but potentially fatal, blood

APA citation: AstraZeneca suffers diabetes drug setback for COVID (2021, April 12) retrieved 7 June 2021 from <https://medicalxpress.com/news/2021-04-astrazeneca-diabetes-drug-setback-covid.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.